|
Session--P13K/mTOR pathway in breast cancer
These sessions require per-registration but are well worth the effort to hear experts discuss the latest science in breast cancer research---bird
Role of P13K/mTOR pathway and its inhibitors in ER+ breast cancer: a new paradigm? CME accredited
e-grandround GR202 - 28 June 2012 - 18:15-19:00 CET
Expert: Fabrice André, Institut de Cancérologie Gustave Roussy, Villejuif, France
Discussant: Nadia Harbeck, Breast Centre, University of Munich, Munich, Germany
http://www.e-eso.net/egrandround.do?...details&id=235
__________________
Male Breast Cancer, DX 5/15/09, IDC, STAGE 1, 1.7 cm, HER2+++, ER+(95%)/PR+(75%), Ki67 40%, grade 3, 0/5 nodes, TX: mastectomy, TCH finished 7/19/10, radiation 6 wks., Tamoxifen on going, bisphosphonate 24 mos.
|
Linear Mode
